Who Paid My Doc
Stephen Cohen
Colon & Rectal Surgery Lewisburg, WV Medical Doctor
NPI 1407825227 CMS profile 199201
233 Dawkins Dr, Lewisburg, WV 24901
General payments
$366
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Stephen Cohen of Lewisburg, WV is reported in the CMS Open Payments database as having received $366 across 9 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 18th percentile of Colon & Rectal Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $102 | 4 | |
| 2024 | General | $44 | 1 | |
| 2022 | General | $22 | 1 | |
| 2021 | General | $161 | 2 | |
| 2019 | General | $37 | 1 |
Beside peers
- Stephen Cohen
- Colon & Rectal Surgery median
- Middle half of Colon & Rectal Surgery
- National median
In program year 2025, general payments to Stephen Cohen were reported at $102. Among 1,481 Colon & Rectal Surgery profiles paid that year, the median was $317 and the middle half received between $109 and $1,248.
Show as a table
| Year | Stephen Cohen | Colon & Rectal Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $37 | $443 | $125–$2,179 | $163 |
| 2020 | $0 | $167 | $53–$931 | $114 |
| 2021 | $161 | $207 | $72–$1,272 | $132 |
| 2022 | $22 | $341 | $111–$1,587 | $149 |
| 2023 | $0 | $322 | $115–$1,420 | $160 |
| 2024 | $44 | $328 | $112–$1,354 | $164 |
| 2025 | $102 | $317 | $109–$1,248 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 1 drugPart D claims
16
Drug cost
$477
Branded share of claims
100%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Albuterol Sulfate Hfa Albuterol Sulfate | Brand | 16 | $477 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero.
Records
9 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Colon & Rectal Surgery in West Virginia
Keri Mayers
Colon & Rectal Surgery · Morgantown, WV
Emily Groves
Colon & Rectal Surgery · Morgantown, WV
Benjamin Dyer
Colon & Rectal Surgery · Charleston, WV
Kim Wiley
Colon & Rectal Surgery · Wheeling, WV
James Lohan
Colon & Rectal Surgery · Charleston, WV
Riaz Cassim
Colon & Rectal Surgery · Morgantown, WV
Related records
Colon & Rectal Surgery in West Virginia
Practitioners in the same specialty and state, ranked by reported value.
All Colon & Rectal Surgery
Everyone recorded under this specialty, nationwide.
Doctors in West Virginia
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.